Open AccessAspirin‐exacerbated respiratory disease: Update on medical management
Author(s) -
White Andrew A.,
Woessner Katharine,
Simon Ronald
Publication year - 2020
Publication title -
world journal of otorhinolaryngology ‐ head and neck surgery
Language(s) - English
Resource type - Journals
eISSN - 2589-1081
pISSN - 2095-8811
DOI - 10.1016/j.wjorl.2020.07.009
Subject(s) - medicine , aspirin , disease , nasal polyps , asthma , intensive care medicine , medical therapy , respiratory disease , quality of life (healthcare) , respiratory system , surgery , lung , nursing
Aspirin‐exacerbated respiratory disease (AERD) is frequently diagnosed in patients with severe type 2 airway inflammation presenting with nasal polyps and severe asthma. It has been associated with a recalcitrant course with high medical and surgical requirements. The advent of recent biological and other targeted treatments show promise in the medical management of patient with AERD. The goal of complete disease control where patients no longer require recurrent surgical procedures, systemic corticosteroid exposure and may live with a stable and relatively normal quality of life is now within reach. Further work is necessary to identify biomarkers predictive of treatment response.